New mRNA trial suspended

Vaccine-associated enhanced respiratory disease Vaccines and Related Biological Products Advisory Committee December 12, 2024 Meeting Announcement Entire briefing document Pediatric RSV vaccine trial enrollment on hold in US, VRBPAC says The halt follows a severe respiratory disease safety signal observed in a July 2024 phase 1 trial of Moderna’s mRNA-1345 and mRNA-1365 vaccine candidates. A phase I trial The effects of the medication on about 20 to 80 healthy volunteers To evaluating safety and ideal dosage 70% move on to phase II This study, safety, tolerability, and immunogenicity Who were the subject